Active, not recruitingPhase 3NCT06673056
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
Studying Ataxia-telangiectasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IntraBio Inc
- Intervention
- N-Acetyl-L-Leucine(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2025 – 2028
Study locations (11)
- University of California Los Angeles, Los Angeles, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- The University of Texas Health (UT Health), Houston, Texas, United States
- University of Cologne, Cologne, Germany
- University of Giessen, Giessen, Germany
- Comenius University Bratislava, Bratislava, Slovakia
- University Hospital L. Pasteur, Košice, Slovakia
- Hospital Universitario La Paz, Madrid, Spain
- University of Bern, Bern, Switzerland
- Royal Papworth Hospital, Cambridge, United Kingdom
- University of Nottingham, Nottingham, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06673056 on ClinicalTrials.govOther trials for Ataxia-telangiectasia
Additional recruiting or active studies for the same condition.